Novo Nordisk lowers its financial forecast in a surprise update, citing lagging sales of its weight-loss drug Wegovy as it fights to regain its leading position in the obesity market https://t.co/LeXFsFYwwh ...

Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks https://t.co/oKWHRePjqF ...

India's Dr Reddy’s Laboratories is gearing up to launch a generic version of semaglutide — the active ingredient in Novo Nordisk's blockbuster weight-loss drug Wegovy — next year https://t.co/DkrWrrJjC2 ...

Hims & Hers went from a scrappy startup to a telehealth powerhouse worth almost $11 billion in just a few years.@g0ingmad explains how the company became the king of knockoff weight-loss drugs https://t.co/MfO25SqQYd https://t.co/tFDtUrda7J ...

China's homemade weight-loss drug, mazdutide, has been approved, and doctors hope it will help more patients get treatment https://t.co/zTXxsN61IH ...

Healthcare & Pharmaceutical Industry - NHS (英国国家医疗服务体系) 开始推广肥胖症药物 [1] - 英国卫生大臣表示，英国大多数肥胖成年人最终可能使用减肥药物，具有“潜力” [1]

Core Viewpoint - Weight-loss drugs are significantly altering consumer dining habits in the U.S., posing a threat to the long-term growth of the restaurant industry, particularly fast-food chains [1][2]. Impact on McDonald's - Redburn Atlantic downgraded McDonald's from Buy to Sell, citing concerns over appetite-suppressing medications reshaping consumer behavior [2]. - Analyst Chris Luyckx estimates McDonald's could lose 28 million annual visits, translating to a revenue loss of $481.5 million, which represents a 0.9% drag on systemwide sales [4]. - The report indicates that the cumulative risk of changing eating habits could escalate, with a potential 10% decline in sales over time [4]. Broader Industry Trends - The report suggests a reversal in the trend of increasing calorie consumption from restaurants, which has nearly tripled since 1977 [5]. - Currently, only 6% of U.S. adults are using GLP-1 medications, but this is expected to rise to 12% of non-type 2 diabetic obese adults by 2030 [6]. Spending Patterns Among Income Groups - Lower-income users of GLP-1 medications have reduced fast-food spending by 14%, with lunch and dinner experiencing the sharpest declines [7]. - Lunch spending among lower-income GLP-1 users has dropped by approximately 9%, while dinner spending has fallen by about 12% [7]. Risks to Other Fast-Food Chains - Domino's Pizza and KFC are identified as facing significant risks, with Domino's projected to lose $129.8 million annually, or 1.4% of its system sales, while KFC may see a 1.2% decline [8]. - Redburn initiated coverage on Domino's with a Sell rating and a 12-month price target of $340, indicating a potential 25% decline from current levels [8]. Vulnerability of Specific Chains - Chains like Domino's, McDonald's, and Pizza Hut are more vulnerable due to their high U.S. exposure, reliance on lower-income consumers, and dependence on group dining occasions [9]. - In contrast, Taco Bell and Chipotle are better positioned due to their diversified traffic patterns, with Taco Bell benefiting from late-night traffic and Chipotle's affluent customer base providing some insulation from the impact [9][10].

Redburn Atlantic earlier downgraded the shares of blue-chip fast food giant McDonald's Corp (NYSE:MCD) to "sell" form "buy," and cut its price target to $260 from $319. This is the third downgrade MCD has received in three days, with the analyst in coverage citing weight-loss drugs like Ozempic as a critical business threat.MCD earlier slipped to its lowest level since April, as it continues to pull away from a late May attempt to conquer long-term resistance at the $320 region. Shares are today testing sup ...